InfuSystem (NYSEAMERICAN:INFU) Shares Cross Above 200-Day Moving Average of $0.00

Shares of InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $6.84. InfuSystem shares last traded at $6.66, with a volume of 16,618 shares traded.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Lake Street Capital raised InfuSystem to a “strong-buy” rating in a research note on Thursday, May 9th. StockNews.com downgraded InfuSystem from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th.

InfuSystem Trading Down 1.5 %

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.51 and a current ratio of 1.87.

InfuSystem (NYSEAMERICAN:INFU) last issued its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported ($0.05) EPS for the quarter. InfuSystem had a return on equity of 0.16% and a net margin of 0.07%. The firm had revenue of $32.00 million for the quarter.

Insider Buying and Selling

In related news, Director Paul Andrew Gendron bought 5,000 shares of the company’s stock in a transaction on Monday, May 20th. The stock was bought at an average cost of $6.54 per share, for a total transaction of $32,700.00. Following the acquisition, the director now directly owns 65,000 shares in the company, valued at $425,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other InfuSystem news, Director Ralph F. Boyd, Jr. purchased 4,000 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The shares were acquired at an average price of $7.13 per share, with a total value of $28,520.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at approximately $42,780. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Paul Andrew Gendron purchased 5,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was acquired at an average cost of $6.54 per share, for a total transaction of $32,700.00. Following the purchase, the director now owns 65,000 shares in the company, valued at $425,100. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 13,000 shares of company stock worth $87,300. 10.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On InfuSystem

Large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in InfuSystem by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 1,083,730 shares of the medical instruments supplier’s stock worth $9,288,000 after acquiring an additional 18,432 shares in the last quarter. Wasatch Advisors LP lifted its stake in InfuSystem by 3.4% during the 4th quarter. Wasatch Advisors LP now owns 846,609 shares of the medical instruments supplier’s stock worth $8,923,000 after acquiring an additional 27,881 shares in the last quarter. Citigroup Inc. lifted its stake in InfuSystem by 124.1% during the 3rd quarter. Citigroup Inc. now owns 50,640 shares of the medical instruments supplier’s stock worth $488,000 after acquiring an additional 28,038 shares in the last quarter. Ranger Investment Management L.P. lifted its stake in InfuSystem by 4.7% during the 4th quarter. Ranger Investment Management L.P. now owns 689,842 shares of the medical instruments supplier’s stock worth $7,271,000 after acquiring an additional 30,835 shares in the last quarter. Finally, First Eagle Investment Management LLC raised its position in InfuSystem by 12.7% in the 1st quarter. First Eagle Investment Management LLC now owns 605,235 shares of the medical instruments supplier’s stock valued at $5,187,000 after purchasing an additional 68,021 shares in the last quarter. Institutional investors and hedge funds own 71.13% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.